Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)


 0.07 (1.18%)

Market Cap$83,363,774

04/20/18  3:59 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $5.86 with a 52 week high of $21.59 and a 52 week low of $5.55.

Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)


Read More

Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results


Read More

Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15


Read More

There are currently no events scheduled.